Inhibition of bacterial RNase P by aminoglycoside–arginine conjugates  by Eubank, Timothy D. et al.
Inhibition of bacterial RNase P by aminoglycoside^arginine conjugates
Timothy D. Eubanka;b, Roopa Biswasa, Milan Jovanovica;b, Alexander Litovchickc,
Aviva Lapidotc, Venkat Gopalana;b;*
aDepartment of Biochemistry, The Ohio State University, Columbus, OH 43210, USA
bThe Ohio State Biochemistry Program, The Ohio State University, Columbus, OH 43210, USA
cDepartment of Organic Chemistry, The Weizmann Institute of Science, 76100 Rehovot, Israel
Received 12 December 2001; accepted 13 December 2001
First published online 4 January 2002
Edited by Thomas L. James
Abstract The potential of RNAs and RNA^protein (RNP)
complexes as drug targets is currently being explored in various
investigations. For example, a hexa-arginine derivative of
neomycin (NeoR) and a tri-arginine derivative of gentamicin
(R3G) were recently shown to disrupt essential RNP interactions
between the trans-activator protein (Tat) and the Tat-responsive
RNA (trans-activating region) in the human immunodeficiency
virus (HIV) and also inhibit HIV replication in cell culture.
Based on certain structural similarities, we postulated that NeoR
and R3G might also be effective in disrupting RNP interactions
and thereby inhibiting bacterial RNase P, an essential RNP
complex involved in tRNA maturation. Our results indicate that
indeed both NeoR and R3G inhibit RNase P activity from
evolutionarily divergent pathogenic bacteria and do so more
effectively than they inhibit partially purified human RNase P
activity. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The recent increase in drug-resistant strains and consequent
pathogenic bacterial infections lends urgency to the design of
novel antibacterial compounds [1]. RNAs and RNA^protein
(RNP) complexes are appealing targets for new drugs because
of their diverse functional roles in various cellular processes
[2]. While the choice of new targets will be primarily in£u-
enced by the objective to e¡ectively disrupt an essential path-
way in bacteria, speci¢city aspects are also major considera-
tions since di¡erences between prokaryotic and eukaryotic
macromolecules (or their assemblages) are critical determi-
nants in the design of a successful antibacterial compound.
Indeed, this is borne out by the currently used drugs that
speci¢cally target bacterial cell wall biosynthesis, protein syn-
thesis, or DNA replication and repair [1]. In the search for
new targets, bacterial RNase P, an endonuclease, merits con-
sideration since it is both essential and structurally distinct
from its eukaryotic counterpart [3^5].
RNase P is a ubiquitous and essential enzyme responsible
for processing the 5P termini of precursor tRNAs (ptRNAs)
and some other cellular RNAs (e.g. p4.5S RNA) involved in
protein biosynthesis [3^5]. The bacterial RNase P holoenzyme
is composed of a catalytic RNA moiety (V350^400 nucleo-
tides) and a protein cofactor (V110^150 amino acid residues).
Although the RNA subunit can catalyze the ptRNA-process-
ing reaction in vitro under non-physiological conditions [6],
the protein subunit, probably due to its role in substrate bind-
ing and catalysis, is absolutely required for RNase P activity
in vivo [7,8]. Therefore, inhibition of bacterial RNase P activ-
ity could be accomplished with a compound that either inter-
acts directly with the catalytic core in the RNA subunit or
disrupts RNP interactions essential for assembly of a func-
tional RNase P holoenzyme.
Aminoglycosides (e.g. neomycin, kanamycin) are small,
polycationic molecules which possess a linked ring system
consisting of aminosugars and an aminocyclitol [9]. These
compounds have found clinical use as antibacterial agents
owing to their ability to bind speci¢cally to prokaryotic
rRNA and inhibit bacterial protein synthesis [10]. Recently,
it has become evident that aminoglycosides as well as their
derivatives bind mRNAs [11], tRNAs [12], viral RNAs [13,14]
and catalytic RNAs [15,16], and that the binding of these
ligands could alter the function of the target RNA. For exam-
ple, neomycin B is a potent inhibitor of ribozymes such as
RNase P and the self-splicing group I intron likely due to its
ability to interfere with the binding of divalent metal ions
essential for RNA catalysis [15,16]. In this study, we have
examined if modi¢ed aminoglycosides (such as the arginine
derivatives of aminoglycosides, NeoR and R3G; Fig. 1) can
inhibit the activity of RNase P derived from certain patho-
genic bacteria and also discriminate between bacterial and
human RNase P.
2. Materials and methods
2.1. Reagents
The procedures for synthesis of NeoR and R3G are described else-
where [17^20].
All oligonucleotides used for PCR were synthesized at the HHMI
Biopolymer/Keck Foundation Biotechnology Resource Laboratory,
Yale University School of Medicine, New Haven, CT, USA. The
18-mer poly(A) oligoribonucleotide was synthesized by Dharmacon
Research, Inc., Boulder, CO, USA. Restriction and modifying en-
zymes were obtained from either New England Biolabs, Beverly,
MA, USA or Gibco Life Technologies, Rockville, MD, USA. T7
RNA polymerase and RNasin were purchased from Promega, Mad-
ison, WI, USA. HiTrap (cation exchange and metal-chelating) col-
umns and [K-32P]GTP were obtained from Amersham Pharmacia Bio-
tech, Piscataway, NJ, USA. All other reagents used were purchased
from either Sigma-Aldrich, St. Louis, MO, USA or Fisher Biotech,
Pittsburgh, PA, USA.
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2.2. Preparation of enzyme and substrate
By using the appropriate primers and genomic DNA as the tem-
plate for PCR-based ampli¢cation, we obtained the genes encoding
the RNA and protein subunits of Neisseria gonorrhoeae, Porphyro-
monas gingivalis, and Streptococcus pneumoniae RNase P. The genes
encoding the RNA subunits, under the control of a T7 RNA poly-
merase promoter, were subcloned into pUC19. The resulting clones
were used for T7 RNA polymerase-mediated run-o¡ in vitro tran-
scription to generate the respective RNase P RNAs, which were
then puri¢ed using a Quick Spin column procedure [21]. The genes
encoding the protein subunits of N. gonorrhoeae, P. gingivalis, and
S. pneumoniae RNase P were subcloned into either pCRT7TOPO or
pBAD (Invitrogen, Carlsbad, CA, USA), two di¡erent expression
vectors. Subsequently, these proteins were overexpressed in Escheri-
chia coli as His6-tagged chimeras and puri¢ed to homogeneity using a
combination of cation exchange and immobilized metal a⁄nity chro-
matography.
All the above mentioned clones were veri¢ed by DNA sequencing
and the molecular masses of the various puri¢ed proteins were con-
¢rmed by electrospray ionization mass spectrometry (data not shown).
The cloning, overexpression and puri¢cation of these bacterial RNase
P RNA and protein subunits will be described elsewhere (Jovanovic,
M. and Gopalan, V., unpublished data); however, if required, these
details will be made available immediately upon request.
The RNA and protein subunits of E. coli RNase P were puri¢ed
according to established procedures [21,22].
Partially puri¢ed human RNase P was a gift from Drs. Taijiao
Jiang and Sidney Altman, Yale University, and prepared as described
elsewhere [23].
The substrate ptRNATyrsu3+ was used for all the inhibition studies
described here and was prepared by in vitro transcription of FokI-
digested pUC19TyrT [21].
2.3. RNase P assays
RNase P activity was measured at 37‡C in the presence or absence
of a de¢ned amount of inhibitors in 50 mM Tris^HCl, pH 7.2, 5%
(w/v) polyethylene glycol 8000, 1 mM NH4Cl, 10 mM spermidine, 10
mM MgCl2, 100 nM ptRNATyrsu3+ [15,21,22]. All enzyme assays
were performed under multiple-turnover conditions (for example,
100 nM ptRNATyrsu3+ and 0.5 nM E. coli RNase P holoenzyme).
The inhibitor was added subsequent to holoenzyme assembly and
allowed to pre-incubate at 37‡C for 5 min prior to addition of the
32P-labeled ptRNATyrsu3+ substrate. After speci¢ed incubation peri-
ods, the reactions were terminated with quenching dye (7 M urea, 10
mM EDTA, 10% (v/v) phenol, 0.05% (w/v) xylene cyanol and 0.05%
(w/v) bromophenol blue) and the products were separated on an 8%
polyacrylamide/7 M urea gel. The extent of substrate cleaved was
quantitated using a PhosphorImager (Molecular Dynamics) and Im-
ageQuant software. The initial velocity values reported are the aver-
ages obtained from two independent experiments and were calculated
by measuring the extent of cleavage at four or ¢ve di¡erent time
points in reactions in which 6 30% of the substrate was cleaved dur-
ing the assay. The IC50 values (i.e. the concentration of inhibitor
required to reduce by 50% the enzymatic activity observed in the
absence of the inhibitor) were estimated by plotting cleavage e⁄ciency
as a function of inhibitor concentration.
3. Results and discussion
3.1. Rationale
The a⁄nity of aminoglycosides for RNA is attributable in
part to their protonated amino groups engaging in electro-
static interactions with the polyanionic target RNAs [24^26].
Structural complementarity between the aminoglycosides and
the target RNAs also results in speci¢c hydrogen bonds and
van der Waals contacts [24,25]. However, since aminoglyco-
sides bind various unrelated cellular RNAs, their promise as
RNA structure-speci¢c drugs will materialize only if the dual
criteria of selectivity and high a⁄nity are ful¢lled. Towards
this goal, various aminoglycoside derivatives displaying struc-
ture-speci¢c determinants have been synthesized and tested in
Tat^trans-activating region (TAR) and Rev^RNA recognition
element (RRE), two RNP complexes that are essential for
human immunode¢ciency virus (HIV) replication [27]. While
Tat protein upon binding to its TAR facilitates transcription
of the HIV genome, the Rev protein through interactions with
its cognate viral RRE aids in nucleocytoplasmic transport and
cytoplasmic accumulation of the viral RNAs [27].
Aminoglycosides, with varying e⁄cacy, can competitively
block the binding of Tat to TAR and Rev to RRE
[13,14,24,25]. Based on this ¢nding and the observation that
both Tat and Rev contain arginine-rich RNA-binding do-
mains, a new class of peptidomimetic TAR and Rev RNA
binders have been constructed by conjugating arginines or
guanidinium moieties to aminoglycosides [17^20,28]. Com-
pared to their unmodi¢ed precursors, the aminoglycoside^ar-
ginine conjugates (AACs; e.g. NeoR, a hexa-arginine deriva-
tive of neomycin; R4K, a tetra-arginine derivative of
kanamycin A) display signi¢cantly higher and selective a⁄nity
to TAR and RRE RNAs. For example, while 100^1000 WM
neomycin B is required to non-competitively inhibit the as-
sembly of Tat^TAR complex, the same is accomplished using
150 nM NeoR; under identical experimental conditions, the
Kd value for assembly of the Tat^TAR complex is V50 nM
[20]. Similarly, NeoR was 100-fold more e¡ective than neo-
mycin B in displacing the Rev-derived peptide from the Rev^
RRE complex (Kd values of 18 nM and 1.8 WM, respectively;
Litovchick and Lapidot, unpublished data). NeoR and R4K
also caused pronounced inhibition of equine infectious anemia
Fig. 1. Structures of NeoR and R3G, two di¡erent AACs.
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virus (EIAV) and HIV-1 replication in cell culture, most likely
due to their ability to disrupt RNP complexes vital for viral
replication [18^20,29]. In contrast to R4K, the conjugate of
kanamycin A and Q-guanidino butyric acid (GB4K) binds
with very low a⁄nity to TAR RNA and does not inhibit
replication of either EIAV or HIV-1 in cell culture
[18,20,29]. Therefore, the guanidinium moieties of the arginine
side chains are clearly not solely responsible for the vast im-
provement in the inhibitory potential of AACs compared to
their unmodi¢ed precursors.
This study on RNase P was prompted by two speci¢c ob-
servations in addition to the results cited above. First, several
aminoglycosides were recently demonstrated to interact with
the RNA subunit of E. coli RNase P in vitro and interfere
with its ptRNA-processing activity [15]. Of the various com-
pounds tested, neomycin B was determined to be the most
potent inhibitor with Ki values of 35 WM and 60 WM for the
reactions catalyzed by the RNA subunit and the RNase P
holoenzyme, respectively [15]. Second, a sequence alignment
of the protein subunit of RNase P from various bacteria re-
veals an arginine-rich consensus (the ‘RNR motif’) which is
likely to be part of the RNA-binding domain in the RNase P
protein cofactor (Fig. 2; [8,22,30]). These ¢ndings led us to
speculate that AACs (like NeoR and R3G) might be e¡ective
inhibitors of bacterial RNase P.
3.2. Inhibition of bacterial and human RNase P by NeoR
and R3G
Subsequent to puri¢cation of the RNA and protein sub-
units of RNase P from E. coli, N. gonorrhoeae, P. gingivalis
and S. pneumoniae, we reconstituted each RNase P holoen-
zyme in vitro and tested the ability of NeoR and R3G to
inhibit the respective RNase P activity. While there is nearly
complete inhibition of E. coli, N. gonorrhoeae and S. pneumo-
niae RNase P activity when either 500 nM NeoR or 1500 nM
R3G is included in the assay mixture, these compounds were
slightly less e¡ective against P. gingivalis RNase P (Fig. 3).
We assayed E. coli RNase P activity in the presence of
increasing concentrations of either NeoR or R3G to deter-
mine their respective IC50 values. For these analyses, the ini-
tial velocities were calculated at various concentrations of the
two inhibitors. NeoR and R3G inhibit E. coli RNase P activ-
ity with IC50 values of V125 nM and 300 nM, respectively
(Fig. 4). Our preliminary screens indicate that the IC50 values
Fig. 2. Partial sequence alignment of the protein subunit of RNase P from various bacteria to illustrate the conservation of an arginine-rich
motif ([22,30]; Jovanovic, M., Braun, E. and Gopalan, V., unpublished observations). The sequences are from E. coli, Coxiella burnetii, N. go-
norrhoeae, Streptomyces bikiniensis, Bacillus subtilis, Synechocystis sp. PCC6803, Borrelia burgdorferi, Chlamydia pneumoniae, Thermotoga mariti-
ma, P. gingivalis, Deinococcus radiodurans and Chlorobium tepidum.
Fig. 3. Inhibition of bacterial RNase P activity by NeoR and R3G. The source of bacterial RNase P and the concentration of inhibitors in the
assay are indicated. The lanes labeled ‘pTyr’ and ‘3’ indicate substrate (without any inhibitor) incubated in the absence and presence of bacte-
rial RNase P, respectively.
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for NeoR- and R3G-mediated inhibition of di¡erent bacterial
RNase P activities are also likely to be in the sub-micromolar
concentration range (Fig. 3; data not shown).
Although RNase P functions as an RNP complex in all
living organisms, there is signi¢cant variation in its structure
and composition. Compared to the simple composition of the
bacterial RNase P holoenzyme (one RNA and one protein
subunit), there is a marked increase in the complexity of hu-
man nuclear RNase P [3]. In addition to a 340-nucleotide long
RNA subunit, at least eight protein subunits ranging in size
from 14 to 115 kDa have been found associated with human
RNase P [3]. Intriguingly, none of these human RNase P
protein subunits possesses the conserved ‘RNR motif’ found
in the bacterial RNase P protein subunit. Moreover, the eu-
karyotic RNase P RNAs are catalytically inactive in vitro
unlike their bacterial counterparts. Despite these di¡erences,
it is important to determine if the activity of human RNase P
is a¡ected by compounds which inhibit bacterial RNase P
activity and could serve as potential antibacterial leads.
Although human RNase P activity was largely una¡ected at
concentrations of NeoR and R3G that are 10-fold greater
than the IC50 values of NeoR and R3G for E. coli RNase
P, there was nearly complete inhibition at 7.5 WM NeoR and
20 WM R3G (Fig. 5). Based on our preliminary analysis we
expect that the IC50 values of NeoR and R3G for human
RNase P will be at least 10-fold greater than those calculated
for E. coli RNase P (data not shown). These inferences are
subject to the caveat that only a partially puri¢ed human
RNase P was used in these experiments.
The polybasic nature of the AACs (Fig. 1) raises the pos-
sibility that the inhibition of RNase P by NeoR and R3G
could stem from their ability to bind the ptRNA substrate
and sequester it from cleavage by RNase P. The following
experiment was performed to address this postulate. By in-
cluding an 18-mer poly(A) RNA in the RNase P assay, we
sought to provide a competitor RNA that could bind NeoR
or R3G through non-speci¢c, electrostatic interactions and
thus reduce their availability for similar interactions with the
ptRNA substrate. Our results indicate that 1 WM poly(A)
RNA, i.e. a 10-fold molar excess over the ptRNA concentra-
tion in the assay, failed to diminish the ability of NeoR or
R3G to inhibit E. coli RNase P activity (Fig. 6). This is also
consistent with our ¢nding that the inhibitory potential of
NeoR and R3G does vary based on the source of enzyme
even when the same ptRNA substrate and identical assay
conditions are employed for the inhibition studies (Figs. 3
and 5). Lastly, the documented observation that a 10-fold
excess of tRNA has no e¡ect on the ability of R3G to disrupt
the RNP complex formed between HIV TAR and a Tat-de-
rived peptide [20] indicates that the AACs have only a weak
a⁄nity to tRNAs. These results cumulatively indicate that the
mechanism of inhibition of bacterial RNase P by NeoR and
R3G is not due to their direct sequestration of the ptRNA
substrate by non-speci¢c interactions.
A few other ¢ndings warrant mention since they relate to
the mechanism of inhibition of RNase P by NeoR and R3G.
First, 1 mM L-arginine does not inhibit E. coli RNase P (Fig.
6). Therefore, the aminoglycoside backbone to which the ar-
ginine residues are conjugated in NeoR and R3G must con-
tribute signi¢cantly to their inhibitory potential. Second, the
inhibition experiments with NeoR and R3G were performed
by adding the inhibitors subsequent to assembly of the respec-
tive bacterial RNase P holoenzymes. However, if the order of
addition was altered such that the inhibitor was added to the
RNA subunit prior to inclusion of the protein cofactor in the
assay reaction, there was no change in the inhibitory potential
of NeoR and R3G (data not shown). Also, both NeoR and
R3G inhibit the ptRNA-processing reaction catalyzed solely
by the RNA subunit of E. coli RNase P in the absence of its
protein cofactor (data not shown). Even though the mecha-
nism of inhibition of the RNase P holoenzyme- and catalytic
RNA-mediated reactions might be di¡erent, these results sug-
gest that the mode of action of NeoR and R3G might involve
their direct binding to the RNA subunit of RNase P. Lastly,
because identical assay conditions were employed for the in-
hibition studies performed with bacterial and human RNase
P, the di¡erence in inhibitory potential of NeoR and R3G
could presumably stem from structural variations in these
two enzymes and the weaker binding a⁄nities of human
RNase P for NeoR and R3G compared to bacterial RNase P.
Fig. 4. Determination of IC50 values for inhibition of E. coli RNase
P activity by NeoR and R3G. The activity observed in the presence
of varying concentrations of either NeoR or R3G is presented as
relative activity compared to that observed with the holoenzyme in
the absence of the inhibitor, which is normalized as 100%. The aver-
ages from at least two independent experiments were used to obtain
the data depicted in this ¢gure.
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3.3. Conclusions
The ¢ndings that E. coli RNase P activity is inhibited with
IC50 values of 60 WM and 125 nM by neomycin B and NeoR,
respectively, suggest that the conjugation of arginine residues
to neomycin B results in a nearly 500-fold more e¡ective in-
hibitor of E. coli RNase P (Fig. 4; [15]). This ¢nding together
with the observation that E. coli RNase P activity is unaf-
fected in the presence of even 1 mM L-arginine (Fig. 6) illus-
trates the premise that the a⁄nity of a ligand for a target
RNA can be enhanced synergistically by fusing two di¡erent
functionalities capable of RNA-binding (i.e. aminoglycosides
and arginine-rich peptides). Moreover, the ¢nding that both
NeoR and R3G are better inhibitors of bacterial RNase P
compared to human RNase P activity (Figs. 4 and 5) validates
the idea that bacterial RNase P-speci¢c inhibitors could either
be rationally designed or identi¢ed from a combinatorial li-
brary of small molecules.
3.4. Speculation
We are currently examining the possibilities that the mech-
anism of inhibition by NeoR and R3G involves either disrup-
tion of RNP interactions in the holoenzyme complex and/or
displacement of essential metal ions in the RNA subunit of
bacterial RNase P.
NeoR and R3G could serve as peptidomimetics and com-
petitively block the protein cofactor of bacterial RNase P
Fig. 5. Inhibition of human RNase P activity by NeoR and R3G. The concentrations of each inhibitor in the assay are indicated. The lanes
labeled ‘pTyr’ and ‘3’ indicate substrate (without any inhibitor) incubated in the absence and presence of human RNase P, respectively.
Fig. 6. E¡ect of poly(A) on the inhibition of E. coli RNase P activity by NeoR and R3G. The concentrations of RNase P holoenzyme and
ptRNA substrate in the assay were 0.5 nM and 100 nM, respectively. The poly(A) oligoribonucleotide was included in the assay at either 2.5-
or 10-fold molar excess over the ptRNA concentration either in the absence of inhibitor (lanes 3 and 4) or in the presence of NeoR or R3G
(lanes 6, 7, 9 and 10). The lack of e¡ect of L-arginine on E. coli RNase P activity is also depicted (lanes 11 and 12). The lanes labeled ‘pTyr’
and ‘3’ indicate substrate (without any inhibitor) incubated in the absence and presence of E. coli RNase P, respectively.
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from binding to the catalytic RNA subunit and thereby dis-
rupt assembly of the RNase P holoenzyme. The proven ability
of (i) neomycin B to occupy the Rev-binding site and thereby
directly displace the Rev peptide from the Rev^RRE complex
[13,14,31], and (ii) NeoR to displace a Tat-derived peptide
from the Tat^TAR complex and a Rev-derived peptide from
the Rev^RRE complex ([20]; Litovchick and Lapidot, unpub-
lished data) serves as precedents for this mechanism. A var-
iation on this theme is the idea that the binding of NeoR and
R3G to the RNA subunit of bacterial RNase P somehow
alters the conformation of the protein-binding site, and there-
by results in weaker a⁄nity for the protein cofactor and dis-
sociation of the RNP complex. This type of an allosteric
mechanism indeed underlies the ability of neomycin B to act
as a non-competitive inhibitor capable of binding the Tat^
TAR RNP complex and promoting dissociation of the Tat-
derived peptide from the Tat^TAR complex [14,32].
An alternative mechanism for inhibition of RNase P by
NeoR and R3G would be compatible with the proven ability
of aminoglycosides and their derivatives to occupy metal-
binding sites in RNAs. For instance, Mikkelsen et al. [15]
performed Pb(II) cleavage experiments with the catalytic
RNA subunit of E. coli RNase P in the absence and presence
of aminoglycosides and demonstrated that the inhibition by
compounds like neomycin B relies on their ability to interfere
with the binding to the catalytic RNA moiety of divalent
metal ions (Mg2) that are critical for the chemical cleavage
step.
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